Oramed Pharmaceuticals Inc. (ORMP) Analysts See $-0.32 EPS; Brookfield Asset Management Raised Physicians Rlty Tr (DOC) Holding By $24.98 Million

June 14, 2018 - By Jacob Smith

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Logo

Brookfield Asset Management Inc increased Physicians Rlty Tr (DOC) stake by 42.34% reported in 2018Q1 SEC filing. Brookfield Asset Management Inc acquired 1.67 million shares as Physicians Rlty Tr (DOC)’s stock declined 1.64%. The Brookfield Asset Management Inc holds 5.60 million shares with $87.17 million value, up from 3.93 million last quarter. Physicians Rlty Tr now has $2.79B valuation. The stock decreased 2.24% or $0.34 during the last trading session, reaching $14.87. About 1.98 million shares traded or 27.25% up from the average. Physicians Realty Trust (NYSE:DOC) has declined 26.95% since June 14, 2017 and is downtrending. It has underperformed by 39.52% the S&P500. Some Historical DOC News: ; 04/05/2018 – Prudential Financial Inc. Exits Position in Physicians Realty; 04/05/2018 – Physicians Realty Trust: 1Q Normalized FFO $49.0 Million, or 26c Per Share; 23/04/2018 – DJ Physicians Realty Trust, Inst Holders, 1Q 2018 (DOC); 04/05/2018 – PHYSICIANS REALTY 1Q NORMALIZED FFO/SHR 26C, EST. 27C; 04/05/2018 – PHYSICIANS REALTY 1Q REV. $105.2M, EST. $101.7M; 04/05/2018 – PHYSICIANS REALTY TRUST QTRLY SAME-STORE CASH NET OPERATING INCOME GROWTH WAS 2.6% YEAR OVER YEAR; 04/05/2018 – Physicians Realty Trust 1Q EPS 6c; 04/05/2018 – Physicians Realty Trust 1Q Rev $105.2M; 16/04/2018 Wheeler Real Estate Investment Trust, Inc. Announces Changes to its Board of Directors

Analysts expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) to report $-0.32 EPS on July, 5.They anticipate $0.17 EPS change or 113.33% from last quarter’s $-0.15 EPS. After having $-0.20 EPS previously, Oramed Pharmaceuticals Inc.’s analysts see 60.00% EPS growth. The stock decreased 4.70% or $0.36 during the last trading session, reaching $7.2. About 20,232 shares traded. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has declined 10.31% since June 14, 2017 and is downtrending. It has underperformed by 22.88% the S&P500. Some Historical ORMP News: ; 30/05/2018 – Oramed Patent Allowed in the US for Oral Admin of Proteins; 23/04/2018 Oramed Pharmaceuticals: 90-day Dosing Study Is a Prerequisite to Phase 3 Confirmatory Studies Under FDA’s BLA; 23/04/2018 – Oramed Pharmaceuticals Study Will Enroll Approximately 240 Patients With Type 2 Diabetes in Multiple Centers Throughout the U.S; 30/05/2018 – Oramed Patent Allowed in the US for Oral Administration of Proteins

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $103.99 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

Investors sentiment decreased to 0.33 in Q1 2018. Its down 2.42, from 2.75 in 2017Q4. It worsened, as 5 investors sold Oramed Pharmaceuticals Inc. shares while 4 reduced holdings. 2 funds opened positions while 1 raised stakes. 234,885 shares or 28.63% less from 329,110 shares in 2017Q4 were reported. Pnc Fincl Svcs Grp owns 21,200 shares. Glenmede Na holds 0% or 20,000 shares. Renaissance Tech Ltd Liability Corp invested in 69,800 shares. Royal Bank & Trust Of Canada has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Bancshares Of America Corporation De accumulated 1,117 shares or 0% of the stock. Tower Rech Cap Lc (Trc) has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Wells Fargo & Com Mn has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Jfs Wealth Advisors Limited Liability, a Pennsylvania-based fund reported 500 shares. Germany-based Deutsche Bank & Trust Ag has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Citigroup holds 6,545 shares or 0% of its portfolio. Morgan Stanley holds 33,887 shares. Financial Architects has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). 2,600 were accumulated by Bancshares Of Montreal Can. Barclays Pcl accumulated 41,186 shares or 0% of the stock.

More news for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) were recently published by: Prnewswire.com, which released: “Oramed to Present at the American Diabetes Association 78th Scientific Sessions” on June 12, 2018. Prnewswire.com‘s article titled: “Oramed Patent Allowed in the US for Oral Administration of Proteins” and published on May 30, 2018 is yet another important article.

Among 4 analysts covering Oramed Pharmaceuticals (NASDAQ:ORMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oramed Pharmaceuticals had 10 analyst reports since August 14, 2015 according to SRatingsIntel. H.C. Wainwright initiated the stock with “Buy” rating in Thursday, October 1 report. The stock of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has “Buy” rating given on Wednesday, November 22 by H.C. Wainwright. The rating was initiated by FBR Capital with “Outperform” on Thursday, November 19. As per Thursday, October 5, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, December 1 by H.C. Wainwright. The stock of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has “Sell” rating given on Friday, August 14 by Zacks. H.C. Wainwright maintained the shares of ORMP in report on Wednesday, June 6 with “Buy” rating. The firm has “Buy” rating by Rodman & Renshaw given on Friday, October 2. The firm has “Buy” rating by B. Riley & Co given on Monday, December 11.

Brookfield Asset Management Inc decreased Companhia De Saneamento Basi (NYSE:SBS) stake by 3.30M shares to 2.25 million valued at $23.87M in 2018Q1. It also reduced Firstenergy Corp (NYSE:FE) stake by 1.96 million shares and now owns 26,589 shares. Enbridge Energy Management L (NYSE:EEQ) was reduced too.

More recent Physicians Realty Trust (NYSE:DOC) news were published by: Seekingalpha.com which released: “Physicians Realty Trust: Healthcare REIT With 24.3% Discount” on May 28, 2018. Also Seekingalpha.com published the news titled: “Physicians Realty Trust: Strong Buy” on June 05, 2018. Businesswire.com‘s news article titled: “How Healthcare Providers Can Benefit from ROFOs and ROFRs” with publication date: June 12, 2018 was also an interesting one.

Among 18 analysts covering Physicians Realty Trust (NYSE:DOC), 14 have Buy rating, 0 Sell and 4 Hold. Therefore 78% are positive. Physicians Realty Trust has $25 highest and $16.0 lowest target. $18.44’s average target is 24.01% above currents $14.87 stock price. Physicians Realty Trust had 64 analyst reports since August 10, 2015 according to SRatingsIntel. On Monday, April 16 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. The rating was maintained by Jefferies with “Hold” on Monday, June 12. On Tuesday, August 11 the stock rating was maintained by Canaccord Genuity with “Buy”. Cantor Fitzgerald maintained the stock with “Buy” rating in Friday, June 30 report. The company was initiated on Friday, December 16 by Jefferies. As per Monday, November 6, the company rating was upgraded by Hilliard Lyons. Jefferies maintained the shares of DOC in report on Monday, October 23 with “Hold” rating. On Friday, March 2 the stock rating was maintained by Robert W. Baird with “Buy”. The stock of Physicians Realty Trust (NYSE:DOC) has “Equal-Weight” rating given on Tuesday, March 20 by Morgan Stanley. BMO Capital Markets maintained Physicians Realty Trust (NYSE:DOC) on Monday, September 4 with “Buy” rating.

Investors sentiment increased to 1.13 in 2018 Q1. Its up 0.04, from 1.09 in 2017Q4. It improved, as 26 investors sold DOC shares while 72 reduced holdings. 35 funds opened positions while 76 raised stakes. 164.93 million shares or 0.70% more from 163.78 million shares in 2017Q4 were reported. Highbridge Mgmt Ltd Liability Company holds 131,000 shares. Macquarie Ltd holds 0.01% or 236,575 shares. Cubist Systematic Strategies Limited Liability Corporation owns 17,421 shares. Invesco Limited has 4.03 million shares for 0.02% of their portfolio. Suntrust Banks holds 0.04% or 427,885 shares. Hightower Advisors Ltd Liability Corp accumulated 29,823 shares. Bank Of Mellon has invested 0.01% of its portfolio in Physicians Realty Trust (NYSE:DOC). Cipher Cap Limited Partnership reported 25,124 shares or 0.05% of all its holdings. Balyasny Asset Management Lc has invested 0.07% in Physicians Realty Trust (NYSE:DOC). The Massachusetts-based Tekla Mgmt Ltd Com has invested 0.16% in Physicians Realty Trust (NYSE:DOC). Thrivent Fincl For Lutherans invested 0.02% of its portfolio in Physicians Realty Trust (NYSE:DOC). Natixis Advsr Ltd Partnership has 0% invested in Physicians Realty Trust (NYSE:DOC) for 25,243 shares. Sfmg Lc has invested 0.28% in Physicians Realty Trust (NYSE:DOC). Northern Trust Corp holds 0.02% or 4.30 million shares in its portfolio. Regions Finance reported 0% of its portfolio in Physicians Realty Trust (NYSE:DOC).

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>